BioRestorative Therapies Inc Market Cap ($10.05 Million)
Market Cap & Net Worth: BioRestorative Therapies Inc (BRTX)
BioRestorative Therapies Inc market cap. BioRestorative Therapies Inc (NASDAQ:BRTX) has a market capitalization of $10.05 Million ($10.05 Million) as of November 4, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #26926 globally and #5603 in its home market, demonstrating a -6.33% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying BioRestorative Therapies Inc's stock price $1.48 by its total outstanding shares 25478170 (25.48 Million). Also see BioRestorative Therapies Inc cash conversion from operations for how efficiently the company converts equity into cash flow.
BioRestorative Therapies Inc Market Cap History (2015–2026)
BioRestorative Therapies Inc market cap history from 2015 to 2026. Data shows change from $433.13 Billion to $37.71 Million (-57.98% CAGR). Check BioRestorative Therapies Inc share price for real-time trading data and today's change.
Index Memberships
BioRestorative Therapies Inc is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Composite
IXIC
|
$40.20 Trillion | 0.00% | #2461 of 3165 |
Weight: BioRestorative Therapies Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
BioRestorative Therapies Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how BioRestorative Therapies Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore net asset growth rate of BioRestorative Therapies Inc to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
83.23x
BioRestorative Therapies Inc's market cap is 83.23 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $336.31 Billion | $36.35K | -$8.64 Million | 9250772.77x | N/A |
| 2017 | $377.08 Billion | $81.00K | -$9.44 Million | 4655270.57x | N/A |
| 2018 | $91.72 Billion | $111.00K | -$12.52 Million | 826319.03x | N/A |
| 2019 | $509.56 Million | $130.00K | -$14.65 Million | 3919.72x | N/A |
| 2020 | $703.20 Million | $77.00K | -$11.27 Million | 9132.43x | N/A |
| 2021 | $110.58 Million | $46.00K | -$44.30 Million | 2403.81x | N/A |
| 2022 | $70.06 Million | $119.80K | -$13.22 Million | 584.85x | N/A |
| 2023 | $44.33 Million | $145.80K | -$10.42 Million | 304.04x | N/A |
| 2024 | $36.43 Million | $401.00K | -$8.98 Million | 90.86x | N/A |
| 2025 | $29.94 Million | $359.70K | -$14.24 Million | 83.23x | N/A |
Competitor Companies of BRTX by Market Capitalization
Companies near BioRestorative Therapies Inc in the global market cap rankings as of November 4, 2026. Also see BRTX asset base for a full breakdown of the balance sheet.
Key companies related to BioRestorative Therapies Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #180 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #368 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #414 globally with a market cap of $68.22 Billion USD ( AU$96.41 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #494 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #180 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $530.76 |
| #368 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $973.36 |
| #414 | CSL Ltd | AU:CSL | $68.22 Billion | AU$198.72 |
| #494 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $228.44 |
Market Capitalization of BioRestorative Therapies Inc (2015–2026)
Market capitalization of BioRestorative Therapies Inc from 2015 to today. Between 2015 and today, BioRestorative Therapies Inc's market cap moved from $433.13 Billion to $ 37.71 Million, with a yearly change of -57.98%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $37.71 Million | +25.96% |
| 2025 | $29.94 Million | -17.83% |
| 2024 | $36.43 Million | -17.81% |
| 2023 | $44.33 Million | -36.73% |
| 2022 | $70.06 Million | -36.64% |
| 2021 | $110.58 Million | -84.28% |
| 2020 | $703.20 Million | +38.00% |
| 2019 | $509.56 Million | -99.44% |
| 2018 | $91.72 Billion | -75.68% |
| 2017 | $377.08 Billion | +12.12% |
| 2016 | $336.31 Billion | -22.35% |
| 2015 | $433.13 Billion | -- |
End of Day Market Cap According to Different Sources
On Nov 4th, 2026 the market cap of BioRestorative Therapies Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $10.05 Million USD |
| MoneyControl | $10.05 Million USD |
| MarketWatch | $10.05 Million USD |
| marketcap.company | $10.05 Million USD |
| Reuters | $10.05 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About BioRestorative Therapies Inc
BioRestorative Therapies, Inc. develops therapeutic products and medical therapies using cell and tissue protocols primarily involving adult stem cells. The company develops programs related to the treatment of disc/spine disease and metabolic disorders. Its products pipeline comprises BRTX-100, a lead cell therapy candidate formulated from autologous cultured mesenchymal stem cells collected fro… Read more